All In Biotech

Drug Trial Radar · NCT07835581

Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation

A Multicenter, Phase 3 Randomized, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Tegoprubart Compared With Tacrolimus in Adult Participants Undergoing De Novo Kidney Transplantation

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 620 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

620

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Mar 2029

Study completion Mar 2033

Sponsor

Lead sponsor
Eledon PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of tegoprubart compared with tacrolimus in adult participants undergoing first kidney transplantation.

Conditions

  • Kidney Transplant Rejection

Interventions

  • TegoprubartDrug

    Tegoprubart administered via IV infusion

  • TacrolimusDrug

    Tacrolimus administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy failure rate at 12 months post-transplant, defined as the first occurrence of biopsy proven acute rejection, graft loss, or deathTime frame: 12 months post-transplant

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.